Fabiani C, et al. - Investigators examined 101 of 69 candidates to evaluate the efficiency of monoclonal anti-tumor necrosis factor (TNF)-α agents in subjects with anterior uveitis (AU) in terms of reduction in recurrences, the modification in visual acuity, and steroid-sparing effect and also to recognize demographic, clinical or therapeutic variables associated with a maintained response to monoclonal TNF-α inhibitors. A decline in the rate of ocular flares from 42.03 events/100 cases/year during the 12 months before the start of TNF-α inhibitors to 2.9 flares/100 patients/year after the start of treatment was noted. They recorded no statistically significant changes in the best corrected visual acuity during the follow-up period. A higher number of cases treated with corticosteroids at baseline was noticed in comparison to that referred to the 12-month evaluation and to the last follow-up visit. The individual clinical, demographic or therapeutic variable associated with long-term treatment duration was represented by concomitant treatment with conventional disease-modifying antirheumatic drugs (cDMARDs).